(Z)-4-Hydroxytamoxifen

CAS No. 68047-06-3

(Z)-4-Hydroxytamoxifen ( trans-4-Hydroxytamoxifen )

Catalog No. M15596 CAS No. 68047-06-3

A major metabolite of tamoxifen, a well-known Estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 58 In Stock
10MG 80 In Stock
25MG 177 In Stock
50MG 347 In Stock
100MG 512 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (Z)-4-Hydroxytamoxifen
  • Note
    Research use only, not for human use.
  • Brief Description
    A major metabolite of tamoxifen, a well-known Estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium.
  • Description
    A major metabolite of tamoxifen, a well-known Estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium; shows a 100-fold increased affinity for ER and approximately 100-times more potent than trans-tamoxifen in suppressing cell growth and plasminogen activator activity.
  • Synonyms
    trans-4-Hydroxytamoxifen
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    ER
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    68047-06-3
  • Formula Weight
    387.51
  • Molecular Formula
    C26H29NO2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 28 mg/mL
  • SMILES
    OC1=CC=C(/C(C2=CC=C(OCCN(C)C)C=C2)=C(C3=CC=CC=C3)\CC)C=C1
  • Chemical Name
    Phenol, 4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Katzenellenbogen BS, et al. Cancer Res. 1984 Jan;44(1):112-9.
2. Desta Z, et al. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
3. Crewe HK, et al. Drug Metab Dispos. 2002 Aug;30(8):869-74.
molnova catalog
related products
  • GDC-0927

    GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.

  • Bazedoxifene

    Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively.

  • PROTAC ERRα ligand 2

    PROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist( IC50 : 5.67 nM)